Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom

Bothrops lanceolatus inflicts severe envenomings in the Lesser Caribbean island of Martinique. Bothrofav®, a monospecific antivenom against B. lanceolatus venom, has proven highly effective at the preclinical and clinical levels. Here, we report a detailed third-generation antivenomics quantitative...

Descripción completa

Detalles Bibliográficos
Autores principales: Pla, Davinia, Rodríguez, Yania, Resiere, Dabor, Mehdaoui, Hossein, Gutiérrez, José María, Calvete, Juan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286001/
https://www.ncbi.nlm.nih.gov/pubmed/32831345
http://dx.doi.org/10.1016/j.toxcx.2018.100004
_version_ 1783544801495351296
author Pla, Davinia
Rodríguez, Yania
Resiere, Dabor
Mehdaoui, Hossein
Gutiérrez, José María
Calvete, Juan J.
author_facet Pla, Davinia
Rodríguez, Yania
Resiere, Dabor
Mehdaoui, Hossein
Gutiérrez, José María
Calvete, Juan J.
author_sort Pla, Davinia
collection PubMed
description Bothrops lanceolatus inflicts severe envenomings in the Lesser Caribbean island of Martinique. Bothrofav®, a monospecific antivenom against B. lanceolatus venom, has proven highly effective at the preclinical and clinical levels. Here, we report a detailed third-generation antivenomics quantitative analysis of Bothrofav®. With the exception of poorly-immunogenic peptides, Bothrofav® immunocaptured all the major protein components. These results, along with previous preclinical and clinical observations, underscore the high neutralizing efficacy of the antivenom against B. lanceolatus venom.
format Online
Article
Text
id pubmed-7286001
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72860012020-06-16 Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom Pla, Davinia Rodríguez, Yania Resiere, Dabor Mehdaoui, Hossein Gutiérrez, José María Calvete, Juan J. Toxicon X Paper Bothrops lanceolatus inflicts severe envenomings in the Lesser Caribbean island of Martinique. Bothrofav®, a monospecific antivenom against B. lanceolatus venom, has proven highly effective at the preclinical and clinical levels. Here, we report a detailed third-generation antivenomics quantitative analysis of Bothrofav®. With the exception of poorly-immunogenic peptides, Bothrofav® immunocaptured all the major protein components. These results, along with previous preclinical and clinical observations, underscore the high neutralizing efficacy of the antivenom against B. lanceolatus venom. Elsevier 2018-12-29 /pmc/articles/PMC7286001/ /pubmed/32831345 http://dx.doi.org/10.1016/j.toxcx.2018.100004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Paper
Pla, Davinia
Rodríguez, Yania
Resiere, Dabor
Mehdaoui, Hossein
Gutiérrez, José María
Calvete, Juan J.
Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom
title Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom
title_full Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom
title_fullStr Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom
title_full_unstemmed Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom
title_short Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom
title_sort third-generation antivenomics analysis of the preclinical efficacy of bothrofav® antivenom towards bothrops lanceolatus venom
topic Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286001/
https://www.ncbi.nlm.nih.gov/pubmed/32831345
http://dx.doi.org/10.1016/j.toxcx.2018.100004
work_keys_str_mv AT pladavinia thirdgenerationantivenomicsanalysisofthepreclinicalefficacyofbothrofavantivenomtowardsbothropslanceolatusvenom
AT rodriguezyania thirdgenerationantivenomicsanalysisofthepreclinicalefficacyofbothrofavantivenomtowardsbothropslanceolatusvenom
AT resieredabor thirdgenerationantivenomicsanalysisofthepreclinicalefficacyofbothrofavantivenomtowardsbothropslanceolatusvenom
AT mehdaouihossein thirdgenerationantivenomicsanalysisofthepreclinicalefficacyofbothrofavantivenomtowardsbothropslanceolatusvenom
AT gutierrezjosemaria thirdgenerationantivenomicsanalysisofthepreclinicalefficacyofbothrofavantivenomtowardsbothropslanceolatusvenom
AT calvetejuanj thirdgenerationantivenomicsanalysisofthepreclinicalefficacyofbothrofavantivenomtowardsbothropslanceolatusvenom

Ejemplares similares